MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.

ABSTRACT:

Objective

To evaluate the efficacy of MAP0004, an orally inhaled dihydroergotamine, for acute treatment of migraine when administered at various time points from within 1 hour to more than 8 hours after migraine onset.

Patients and methods

This post hoc subanalysis was conducted using data from 902 patients enrolled in a randomized, double-blind, placebo-controlled, 2-arm, phase 3, multicenter study conducted from July 14, 2008, through March 23, 2009. End points were 2-hour pain relief and pain-free rates in patients who treated a migraine in ≤1 hour, from >1 hour to ≤4 hours, from >4 to ≤8 hours, or in >8 hours after onset of migraine, given that patients may be unwilling or unable to initiate treatment at headache inception.

Results

Treatment with MAP0004 was signi

SUBMITTER: Tepper SJ 

PROVIDER: S-EPMC3184024 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature